Cargando…

Clinical Applicability of the Specific Risk Score of Dementia in Type 2 Diabetes in the Identification of Patients with Early Cognitive Impairment: Results of the MOPEAD Study in Spain

Introduction: Although the Diabetes Specific Dementia Risk Score (DSDRS) was proposed for predicting risk of dementia at 10 years, its usefulness as a screening tool is unknown. For this purpose, the European consortium MOPEAD included the DSDRS within the specific strategy for screening of cognitiv...

Descripción completa

Detalles Bibliográficos
Autores principales: Ortiz Zuñiga, Angel Michael, Simó, Rafael, Rodriguez-Gómez, Octavio, Hernández, Cristina, Rodrigo, Adrian, Jamilis, Laura, Campo, Laura, Alegret, Montserrat, Boada, Merce, Ciudin, Andreea
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7565958/
https://www.ncbi.nlm.nih.gov/pubmed/32847012
http://dx.doi.org/10.3390/jcm9092726
_version_ 1783596047519449088
author Ortiz Zuñiga, Angel Michael
Simó, Rafael
Rodriguez-Gómez, Octavio
Hernández, Cristina
Rodrigo, Adrian
Jamilis, Laura
Campo, Laura
Alegret, Montserrat
Boada, Merce
Ciudin, Andreea
author_facet Ortiz Zuñiga, Angel Michael
Simó, Rafael
Rodriguez-Gómez, Octavio
Hernández, Cristina
Rodrigo, Adrian
Jamilis, Laura
Campo, Laura
Alegret, Montserrat
Boada, Merce
Ciudin, Andreea
author_sort Ortiz Zuñiga, Angel Michael
collection PubMed
description Introduction: Although the Diabetes Specific Dementia Risk Score (DSDRS) was proposed for predicting risk of dementia at 10 years, its usefulness as a screening tool is unknown. For this purpose, the European consortium MOPEAD included the DSDRS within the specific strategy for screening of cognitive impairment in type 2 diabetes (T2D) patients attended in a third-level hospital. Material and Methods: T2D patients > 65 years, without known cognitive impairment, attended in a third-level hospital, were evaluated. As per MOPEAD protocol, patients with MMSE ≤ 27 or DSDRS ≥ 7 were referred to the memory clinic for complete neuropsychological assessment. Results: 112 T2D patients were recruited. A total of 82 fulfilled the criteria for referral to the memory unit (43 of them declined referral: 48.8% for associated comorbidities, 37.2% lack of interest, 13.95% lack of social support). At the Fundació ACE’s Memory Clinic, 34 cases (87.2%) of mild cognitive impairment (MCI) and 3 cases (7.7%) of dementia were diagnosed. The predictive value of DSDRS ≥ 7 as a screening tool of cognitive impairment was AUROC = 0.739, p 0.024, CI 95% (0.609–0.825). Conclusions: We found a high prevalence of unknown cognitive impairment in TD2 patients who attended a third-level hospital. The DSDRS was found to be a useful screening tool. The presence of associated comorbidities was the main factor of declining referral.
format Online
Article
Text
id pubmed-7565958
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-75659582020-10-26 Clinical Applicability of the Specific Risk Score of Dementia in Type 2 Diabetes in the Identification of Patients with Early Cognitive Impairment: Results of the MOPEAD Study in Spain Ortiz Zuñiga, Angel Michael Simó, Rafael Rodriguez-Gómez, Octavio Hernández, Cristina Rodrigo, Adrian Jamilis, Laura Campo, Laura Alegret, Montserrat Boada, Merce Ciudin, Andreea J Clin Med Article Introduction: Although the Diabetes Specific Dementia Risk Score (DSDRS) was proposed for predicting risk of dementia at 10 years, its usefulness as a screening tool is unknown. For this purpose, the European consortium MOPEAD included the DSDRS within the specific strategy for screening of cognitive impairment in type 2 diabetes (T2D) patients attended in a third-level hospital. Material and Methods: T2D patients > 65 years, without known cognitive impairment, attended in a third-level hospital, were evaluated. As per MOPEAD protocol, patients with MMSE ≤ 27 or DSDRS ≥ 7 were referred to the memory clinic for complete neuropsychological assessment. Results: 112 T2D patients were recruited. A total of 82 fulfilled the criteria for referral to the memory unit (43 of them declined referral: 48.8% for associated comorbidities, 37.2% lack of interest, 13.95% lack of social support). At the Fundació ACE’s Memory Clinic, 34 cases (87.2%) of mild cognitive impairment (MCI) and 3 cases (7.7%) of dementia were diagnosed. The predictive value of DSDRS ≥ 7 as a screening tool of cognitive impairment was AUROC = 0.739, p 0.024, CI 95% (0.609–0.825). Conclusions: We found a high prevalence of unknown cognitive impairment in TD2 patients who attended a third-level hospital. The DSDRS was found to be a useful screening tool. The presence of associated comorbidities was the main factor of declining referral. MDPI 2020-08-24 /pmc/articles/PMC7565958/ /pubmed/32847012 http://dx.doi.org/10.3390/jcm9092726 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Ortiz Zuñiga, Angel Michael
Simó, Rafael
Rodriguez-Gómez, Octavio
Hernández, Cristina
Rodrigo, Adrian
Jamilis, Laura
Campo, Laura
Alegret, Montserrat
Boada, Merce
Ciudin, Andreea
Clinical Applicability of the Specific Risk Score of Dementia in Type 2 Diabetes in the Identification of Patients with Early Cognitive Impairment: Results of the MOPEAD Study in Spain
title Clinical Applicability of the Specific Risk Score of Dementia in Type 2 Diabetes in the Identification of Patients with Early Cognitive Impairment: Results of the MOPEAD Study in Spain
title_full Clinical Applicability of the Specific Risk Score of Dementia in Type 2 Diabetes in the Identification of Patients with Early Cognitive Impairment: Results of the MOPEAD Study in Spain
title_fullStr Clinical Applicability of the Specific Risk Score of Dementia in Type 2 Diabetes in the Identification of Patients with Early Cognitive Impairment: Results of the MOPEAD Study in Spain
title_full_unstemmed Clinical Applicability of the Specific Risk Score of Dementia in Type 2 Diabetes in the Identification of Patients with Early Cognitive Impairment: Results of the MOPEAD Study in Spain
title_short Clinical Applicability of the Specific Risk Score of Dementia in Type 2 Diabetes in the Identification of Patients with Early Cognitive Impairment: Results of the MOPEAD Study in Spain
title_sort clinical applicability of the specific risk score of dementia in type 2 diabetes in the identification of patients with early cognitive impairment: results of the mopead study in spain
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7565958/
https://www.ncbi.nlm.nih.gov/pubmed/32847012
http://dx.doi.org/10.3390/jcm9092726
work_keys_str_mv AT ortizzunigaangelmichael clinicalapplicabilityofthespecificriskscoreofdementiaintype2diabetesintheidentificationofpatientswithearlycognitiveimpairmentresultsofthemopeadstudyinspain
AT simorafael clinicalapplicabilityofthespecificriskscoreofdementiaintype2diabetesintheidentificationofpatientswithearlycognitiveimpairmentresultsofthemopeadstudyinspain
AT rodriguezgomezoctavio clinicalapplicabilityofthespecificriskscoreofdementiaintype2diabetesintheidentificationofpatientswithearlycognitiveimpairmentresultsofthemopeadstudyinspain
AT hernandezcristina clinicalapplicabilityofthespecificriskscoreofdementiaintype2diabetesintheidentificationofpatientswithearlycognitiveimpairmentresultsofthemopeadstudyinspain
AT rodrigoadrian clinicalapplicabilityofthespecificriskscoreofdementiaintype2diabetesintheidentificationofpatientswithearlycognitiveimpairmentresultsofthemopeadstudyinspain
AT jamilislaura clinicalapplicabilityofthespecificriskscoreofdementiaintype2diabetesintheidentificationofpatientswithearlycognitiveimpairmentresultsofthemopeadstudyinspain
AT campolaura clinicalapplicabilityofthespecificriskscoreofdementiaintype2diabetesintheidentificationofpatientswithearlycognitiveimpairmentresultsofthemopeadstudyinspain
AT alegretmontserrat clinicalapplicabilityofthespecificriskscoreofdementiaintype2diabetesintheidentificationofpatientswithearlycognitiveimpairmentresultsofthemopeadstudyinspain
AT boadamerce clinicalapplicabilityofthespecificriskscoreofdementiaintype2diabetesintheidentificationofpatientswithearlycognitiveimpairmentresultsofthemopeadstudyinspain
AT ciudinandreea clinicalapplicabilityofthespecificriskscoreofdementiaintype2diabetesintheidentificationofpatientswithearlycognitiveimpairmentresultsofthemopeadstudyinspain